Struggling with Alzheimer's launch, Biogen couldn't present 'clear case for growth' outside of Aduhelm: analyst

By this point in Biogen’s highly scrutinized rollout of Alzheimer’s drug Aduhelm, market watchers expected that thousands of U.S. patients would be on the treatment. That reportedly hasn’t been the case, and some analysts are now concerned that Biogen doesn’t have enough pipeline prospects to shield it against potentially disappointing Aduhelm sales.